Cilostazol-Rosuvastatin Safety Study: Korean EHR Cohort from 2004-2025

A retrospective cohort study from 2004 to 2025 using electronic health records from Gachon University Gil Hospital. It compares the 1-year safety of cilostazol-rosuvastatin combination therapy (n=262) versus cilostazol monotherapy (n=6,323) in a Korean population. The dataset was created by Woo-young Shin and last updated on 2026-04-17.

Use Cases

• Compare incidence rates of atherosclerotic cardiovascular disease (ASCVD) based on treatment group and baseline comorbidities.
• Analyze bleeding and myopathy risk profiles for combination therapy versus monotherapy.
• Study changes in liver enzyme (AST/ALT) levels and platelet counts over a 365-day follow-up period.
• Investigate the impact of baseline conditions like chronic kidney disease and diabetes on safety outcomes.

Strengths

• Includes data from 6,585 total patients (262 combination, 6,323 monotherapy) for statistical power.
• Provides 1-year follow-up data with primary safety outcomes measured at 90 and 365 days.
• Contains specific baseline comorbidity percentages (e.g., 45.8% CKD in combination group).
• Uses the Observational Medical Outcomes Partnership (OMOP) Common Data Model for standardization.

Limitations

• Row count for the underlying dataset is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single hospital in Korea, which may limit generalizability to other populations.

Provenance

Source

Observational Medical Outcomes Partnership (OMOP) Common Data Model from Gachon University Gil Hospital.

Collection Method

Retrospective cohort study using electronic health records.

Time Range

2004–2025

Freshness

Last updated 2026-04-17 05:21:31; freshness should be verified.

Geography

South Korea (single hospital)